Literature DB >> 272084

Levamisole as an immunotherapeutic agent in the treatment of cancer.

W K Amery.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 272084     DOI: 10.1007/bf01556185

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


× No keyword cloud information.
  8 in total

1.  Effect of lung irradiation on the incidence of pulmonary metastases and its mechanism.

Authors:  Y Tanaka
Journal:  Acta Radiol Ther Phys Biol       Date:  1976-04

2.  Immunopotentiation with levamisole in resectable bronchogenic carcinoma: a double-blind controlled trial; Study Group for Bronchogenic Carcinoma.

Authors: 
Journal:  Br Med J       Date:  1975-08-23

3.  Letter: In-vitro resotration by levamisole of thymus-derived lymphocyte function in Hodgkin's disease.

Authors:  M Biniaminov; B Ramot
Journal:  Lancet       Date:  1975-02-22       Impact factor: 79.321

4.  Effect of levamisole (NSC-177023) on DNA synthesis by lymphocytes from immunosuppressed C57BL mice.

Authors:  W A Woods; M J Filegelman; M A Chirigos
Journal:  Cancer Chemother Rep       Date:  1975 May-Jun

5.  In vitro parameters of cell-mediated immune reactions in healthy individuals following immune-stimulation attempts with levamisole.

Authors:  H Thulin; K Thestrup-Pedersen; J Ellegaard
Journal:  Acta Allergol       Date:  1975-04

6.  Levamisole in advanced human breast cancer.

Authors:  A F Rojas; J N Feierstein; E Mickiewicz; H Glait; A J Olivari
Journal:  Lancet       Date:  1976-01-31       Impact factor: 79.321

Review 7.  Double-blind levamisole trial in resectable lung cancer.

Authors:  W K Amery
Journal:  Ann N Y Acad Sci       Date:  1976       Impact factor: 5.691

8.  Adjuvant treatment with levamisole in cancer: a review of experimental and clinical data.

Authors:  W K Amery; F Spreafico; A F Rojas; E Denissen; M Chirigos
Journal:  Cancer Treat Rev       Date:  1977-09       Impact factor: 12.111

  8 in total
  1 in total

1.  Adjuvant therapy in colorectal cancer.

Authors:  A K House
Journal:  J R Soc Med       Date:  1984-06       Impact factor: 18.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.